Accustem Sciences Inc.
Accustem Sciences Inc. is a clinical-stage diagnostics company focused on developing genomic tests for oncology decision-making. Its core programs are MSC (MicroRNA Signature Classifier) for patients with lung nodules and StemPrintER for early-stage breast cancer, with plans to expand the StemPrint platform into additional tumor types. The company is still in the development and commercialization-build phase and has not yet generated product revenue. It is working through laboratory transfer, CLIA certification, and reimbursement milestones before launching its tests commercially in the United States.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueProprietary molecular tests intended to support cancer diagnosis and treatment decisions, including MSC and StemPrintER.
Commodity tests offered alongside the core classifiers to improve customer value and laboratory utilization.
Customers
Accustem’s customers are expected to be clinicians and healthcare systems that need genomic information to guide oncology care. For MSC, the target use case is patients with lung nodules, where the test is intended to help determine clinical management and support reimbursement-backed adoption. For StemPrintER, the customer is the breast cancer care pathway, especially providers treating early-stage breast cancer who need risk stratification and decision support. The company also expects ancillary tests such as next-generation sequencing, IHC receptor status, and hereditary panels to be purchased as add-ons that increase the value of each case and improve laboratory economics.
Clinicians and institutions evaluating lung nodules who would use MSC to support diagnosis and management decisions.
Oncology providers treating early-stage breast cancer who would use StemPrintER to inform care decisions.
Customers purchasing add-on molecular tests such as next-generation sequencing, IHC receptor status, and hereditary panels.
Commercial laboratory partners that process, test, and report results for commercial samples.
Strategy
Accustem’s strategy is to move from clinical development into commercial launch by completing the operational milestones required for reimbursement-ready testing. The company is prioritizing laboratory transfer, commercial lab validation, and CLIA certification so that MSC can be reported for clinical use and billed to payers. It is also broadening the value proposition by bundling ancillary tests with its core assays, which should improve customer utility and laboratory economics. Longer term, management wants to extend the StemPrint platform beyond breast cancer into additional tumor types to widen the addressable market.
MSC needs clinical validation, laboratory transfer, and reimbursement readiness before it can generate revenue.
Peer-reviewed publications and payer acceptance are required for adoption and monetization of the genomic classifier.
Broader tumor-type coverage could increase the commercial opportunity beyond breast cancer.
Geography
Accustem is headquartered and operates from New York, NY and London, UK, while substantially all of its assets are located in the United States. The company’s initial commercialization focus is the U.S. market, where it expects to launch MSC first and where it estimates a large addressable revenue opportunity. It has partnered with EmeritusDx in Lake Forest, California to support commercial laboratory processing. Management has also indicated that it may expand into other markets later, depending on clinical need and revenue opportunity.
Risks
The company faces execution risk because it has no approved commercial products and must complete several technical and regulatory milestones before launch. Its ability to commercialize depends on successful laboratory transfer, CLIA certification, and payer reimbursement, any of which could be delayed or fail. As a diagnostics developer, it also faces scientific and clinical adoption risk: the tests must continue to demonstrate utility in real-world care and maintain support from physicians and payers. Financially, the business is exposed to funding risk because it has no revenue, no committed external capital, and ongoing losses, while internal control weaknesses and limited accounting resources add reporting and operational risk.
The company has no revenue, no committed external funding, and ongoing losses.
Exposure: Liquidity and operating continuity
MSC and StemPrintER require lab transfer, validation, and CLIA certification before clinical launch.
Exposure: Launch timing and first revenue generation
The company states that peer-reviewed publications and payer reimbursement are necessary for commercialization.
Exposure: Adoption and pricing
Management disclosed ineffective controls due to lack of accounting resources and inadequate segregation of duties.
Exposure: Financial reporting reliability
Accounting
Judgemental itemsManagement disclosed ineffective controls due to lack of accounting resources, weak monitoring, and poor segregation of duties.
Impact: Raises the risk of financial statement error and delayed reporting
Quarterly R&D changes reflect laboratory work, consulting, and patent-related spending.
Impact: Makes operating loss trends less comparable across periods
The company has no approved commercial products and no revenue to date.
Impact: Financial statements are dominated by expense recognition and financing activity
Similar listed companies
Publicly listed companies with a comparable business focus.
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Achieve Life Sciences, Inc
ACHV · In Vitro & In Vivo Diagnostic Substances
Exact Sciences Corp
Services-Medical Laboratories
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
NextCure, Inc.
NXTC · Pharmaceutical Preparations
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Last updated: 24/09/2026